LY3471851 + levocetirizine

This drug is a **combination therapy** of LY3471851, which is an investigational monoclonal antibody, and **levocetirizine**, a second-generation non-sedating antihistamine. Levocetirizine acts primarily as a **selective antagonist of the histamine H1 receptor** and is widely approved for the treatment of allergic rhinitis and chronic urticaria. LY3471851 is a **biologic agent** under research by Eli Lilly, categorized as an **anti-IL-17 monoclonal antibody** intended to modulate inflammatory immunological diseases. The combination with levocetirizine is not reported as an approved or standard fixed-dose product. No clinical evidence was found for the efficacy or safety of the combination of LY3471851 plus levocetirizine; studies addressing levocetirizine combinations most frequently combine it with montelukast or other agents for allergic or urticarial indications[2][3][4].